Science & Research

At Albion, we make claims based on sound science and research. Our premier iron product, Ferrochel® (ferrous bisglycinate chelate) has been studied extensively in world-wide clinical trials.

The following abstracts have been selected from our research database because they contain the most informative research for consumer needs. Please feel free to contact us if you have any questions about this information.

  • The absorption and metabolism of iron amino acid chelate +

    Ashmead, HD., Archivos Latinoamericanos de Nutricion, Vol 51, No. 1, 2001, (Albion Laboratories, Inc.)

    This paper summarizes several studies which describe significant increases in the intestinal absorption of iron from iron amino acid chelate compared to inorganic iron salts. While these increased uptakes of iron from the amino acid chelate into mucosal tissue are highly significant, this paper also demonstrates that there is a mechanism in the mucosal tissue which controls the quantity of iron from the amino acid chelate that is transferred to the plasma. For example, the higher the hemoglobin value, the less iron transferred. When considered together, these studies demonstrate that iron amino acid chelate is both a safe and effective source of iron for treatment of iron deficiencies.


  • Effectiveness of Treatment of Iron-Deficiency Anemia in Infants and Young Children With Ferrous Bisglycinate Chelate +

    Pineda, O et al., Nutrition 17:381 - 384, 2001

    Forty infants, 6 to 36 months old, with iron-deficiency anemia (hemoglobin < 11 g/dL) were matched and assigned to two groups. One group received FeS0(4) and the other received ferrous bisglycinate chelate at a dose of 5 mg of Fe daily per kilogram of body weight for 28 d. Both groups had significant hemoglobin increases (P < 0.001), but only the group treated with ferrous bisglycinate chelate had significant increases (P < 0.005) in plasma ferritin. Apparent iron bioavailabilities were calculated at 26.7% for FeS0(4) and 90.9% for ferrous bisglycinate chelate. Regression analysis indicated that absorption of both sources of iron were similarly regulated by the body according to changes in hemoglobin. We concluded that ferrous bisglycinate chelate is the iron of choice for the treatment of infants with iron-deficiency anemia because of its high bioavailability and good regulation.


  • Efficacy trials of a micronutrient dietary supplement in schoolchildren and pregnant women in Tanzania +

    Latham M. et al., Food and Nutrition Bulletin, Vol. 24, No. 4, S120-128 (See A11-15-1900 for a copy of the Journal)

    Traditionally, the main strategies used to control micronutrient deficiencies have been food diversification, consumption of medicinal supplements, and food fortification. In Tanzania, we conducted efficacy trials using a dietary supplement as a fourth approach. These were randomized, double-blind, placebo-controlled efficacy trials conducted separately first in children and later in pregnant women. The dietary supplement was a powder used to prepare an orange flavored beverage. In the school trial, children consumed 25 g per school day attended. In the pregnancy trial, women consumed the contents of two 25-g sachets per day with meals. This dietary supplement, unlike most medicinal supplements, provided 11 micronutrients, including iron and vitamin A, in physiologic amounts. In both trials, we compared changes in subjects consuming either the fortified or the nonfortified supplement. Measures of iron and vitamin A status were similar in the groups at the baseline examination, but significantly different at follow-up, always in favor of the fortified groups. Children receiving the fortified supplement had significantly improved anthropometric measures when compared with controls. At four weeks postpartum, the breast milk of a supplemented group of women had significantly higher mean retinol content than did the milk of mothers consuming the nonfortified supplement. The advantages of using a fortified dietary supplement, compared with other approaches, include its ability to control several micronutrient deficiencies simultaneously; the use of physiologic amounts of nutrients, rather than megadoses that require medical supervision; and the likelihood of better compliance than with the use of pills because subjects liked the beverage used in these trials.


  • Relative effectiveness of iron bisglycinate chelate (Ferrochel®) and ferrous sulfate in the control of iron deficiency in pregnant women +

    Szarfarc, SD et al., Archivos Latinoamericanos de Nutricion, Vol. 51, No. 1, 2001 (Sao Paulo University, National University of Cajamarca, Peru)

    The relative effectiveness of daily supplementation of iron deficiency during pregnancy using 15 mg per day of iron from iron bisglycinate chelate (71 pregnant women) or 40 mg iron from ferrous sulfate (74 pregnant women) was evaluated by measuring hemoglobin, transferrin saturation, and serum ferritin at the beginning of the study (<20 weeks of pregnancy) and at 20-30 weeks and 30-40 weeks thereafter. Ingestion for 13 weeks or more was considered adequate. 73% of the Ferrochel consuming group and 35% of the ferrous sulfate consuming group were considered to have taken the treatment adequately. The decrease in levels of all the measured parameters was significantly less pronounced in the group that consumed Ferrochel in spite of the lower treatment dose. Iron depletion was found in 30.8% of the women treated with Ferrochel and in 54.5% of the women that consumed ferrous sulfate. Of the factors responsible for non compliance, taste was reported in 29.8% of the ferrous sulfate consumers and none in the groups that consumed Ferrochel. It is concluded that daily supplementation with Ferrochel was significantly more effective, in spite of the lower dose, than supplementation with ferrous sulfate.


  • Safety Evaluation of Ferrous Bisglycinate Chelate +

    Borzelleca, J, and Jeppsen, R., Food and Chemical Toxicology 37 (1999) 723-731

    Ferrous bisglycinate chelate (Ferrochel®) is a highly stable chelate that can be added to most foods. Data from human and animal studies indicate that the ferrous iron is readily bioavailable with fewer side effects than the more commonly used iron salts. The acute oral LD50 for male and female Sprague-Dawley (S-D) rats is 2800 mg/kg body weight (560 mg/kg body weight iron [confidence limit (CL) 399-786] as the active ingredient). Male and female CD (Sprague Dawley-derived) rats were fed ferrous bisglycinate as a dietary admixture at doses of 0, 100, 250 and 500 mg/kg body weight/day. There were no biologically or statistically significant dose-related differences between the control and treated animals with respect to body weight gain, food consumption, food efficiency, behavioural effects, clinical chemistries, haematology, absolute and relative organ weights, or gross and microscopic findings. Hepatic non-heme iron concentrations were elevated, indicating that the ferrous iron had been absorbed. The no-observed-adverse-effect level (NOAEL) was 500 mg/kg body weight/day, the highest dose tested.


  • 1
Sign Up For Free Email

Subscribe Now!

Vitamin Angels logo.

Follow Us

 For info on Albion's other minerals, visit Albion Nutritional Facts

© 2019 Albion Laboratories, Inc. All rights reserved.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
Powered by Astroid Framework